Menu
GeneBe

rs61754118

Variant summary

Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2

The NM_000465.4(BARD1):c.2212A>G(p.Ile738Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00768 in 1,614,204 control chromosomes in the GnomAD database, including 100 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0075 ( 9 hom., cov: 32)
Exomes 𝑓: 0.0077 ( 91 hom. )

Consequence

BARD1
NM_000465.4 missense

Scores

1
17

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:19

Conservation

PhyloP100: 2.38
Variant links:
Genes affected
BARD1 (HGNC:952): (BRCA1 associated RING domain 1) This gene encodes a protein which interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, it shares homology with the 2 most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. This protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. This protein may be the target of oncogenic mutations in breast or ovarian cancer. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2013]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.0065450966).
BP6
Variant 2-214728798-T-C is Benign according to our data. Variant chr2-214728798-T-C is described in ClinVar as [Likely_benign]. Clinvar id is 136501.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr2-214728798-T-C is described in Lovd as [Benign].
BS1
Variant frequency is greater than expected in population amr. gnomad4 allele frequency = 0.0075 (1143/152324) while in subpopulation AMR AF= 0.0131 (200/15290). AF 95% confidence interval is 0.0116. There are 9 homozygotes in gnomad4. There are 543 alleles in male gnomad4 subpopulation. This position pass quality control queck.
BS2
High AC in GnomAd at 1143 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
BARD1NM_000465.4 linkuse as main transcriptc.2212A>G p.Ile738Val missense_variant 11/11 ENST00000260947.9

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
BARD1ENST00000260947.9 linkuse as main transcriptc.2212A>G p.Ile738Val missense_variant 11/111 NM_000465.4 P2Q99728-1

Frequencies

GnomAD3 genomes
AF:
0.00751
AC:
1143
AN:
152206
Hom.:
9
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00577
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0131
Gnomad ASJ
AF:
0.0233
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00310
Gnomad FIN
AF:
0.000470
Gnomad MID
AF:
0.0633
Gnomad NFE
AF:
0.00798
Gnomad OTH
AF:
0.0191
GnomAD3 exomes
AF:
0.00774
AC:
1945
AN:
251344
Hom.:
21
AF XY:
0.00774
AC XY:
1051
AN XY:
135836
show subpopulations
Gnomad AFR exome
AF:
0.00523
Gnomad AMR exome
AF:
0.0116
Gnomad ASJ exome
AF:
0.0276
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00317
Gnomad FIN exome
AF:
0.000739
Gnomad NFE exome
AF:
0.00839
Gnomad OTH exome
AF:
0.0187
GnomAD4 exome
AF:
0.00770
AC:
11262
AN:
1461880
Hom.:
91
Cov.:
32
AF XY:
0.00771
AC XY:
5610
AN XY:
727244
show subpopulations
Gnomad4 AFR exome
AF:
0.00702
Gnomad4 AMR exome
AF:
0.0126
Gnomad4 ASJ exome
AF:
0.0279
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00318
Gnomad4 FIN exome
AF:
0.000899
Gnomad4 NFE exome
AF:
0.00761
Gnomad4 OTH exome
AF:
0.0112
GnomAD4 genome
AF:
0.00750
AC:
1143
AN:
152324
Hom.:
9
Cov.:
32
AF XY:
0.00729
AC XY:
543
AN XY:
74498
show subpopulations
Gnomad4 AFR
AF:
0.00575
Gnomad4 AMR
AF:
0.0131
Gnomad4 ASJ
AF:
0.0233
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00310
Gnomad4 FIN
AF:
0.000470
Gnomad4 NFE
AF:
0.00798
Gnomad4 OTH
AF:
0.0189
Alfa
AF:
0.00940
Hom.:
20
Bravo
AF:
0.00884
TwinsUK
AF:
0.00405
AC:
15
ALSPAC
AF:
0.00778
AC:
30
ESP6500AA
AF:
0.00386
AC:
17
ESP6500EA
AF:
0.00814
AC:
70
ExAC
AF:
0.00732
AC:
889
Asia WGS
AF:
0.00289
AC:
10
AN:
3478
EpiCase
AF:
0.00971
EpiControl
AF:
0.0123

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:19
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Familial cancer of breast Benign:7
Benign, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesNov 22, 2023- -
Likely benign, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaJan 13, 2018This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. -
Benign, criteria provided, single submitterclinical testingInstitute of Human Genetics, University of Leipzig Medical CenterJan 01, 2019- -
Benign, criteria provided, single submitterclinical testingMyriad Genetics, Inc.Feb 24, 2023This variant is considered benign. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. -
Benign, criteria provided, single submitterclinical testingKCCC/NGS Laboratory, Kuwait Cancer Control CenterJul 07, 2023- -
Benign, criteria provided, single submitterclinical testingCounsylMay 25, 2016- -
Benign, criteria provided, single submitterclinical testingInvitaeFeb 01, 2024- -
not specified Benign:5
Benign, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoJul 24, 2020- -
Benign, criteria provided, single submitterclinical testingGeneDxOct 18, 2013This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
Likely benign, criteria provided, single submitterclinical testingCenter for Genomic Medicine, Rigshospitalet, Copenhagen University HospitalAug 15, 2023- -
Benign, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact SciencesNov 28, 2016- -
Benign, criteria provided, single submitterclinical testingGenetic Services Laboratory, University of ChicagoSep 18, 2020- -
Hereditary cancer-predisposing syndrome Benign:4
Benign, criteria provided, single submitterclinical testingVantari GeneticsDec 18, 2015- -
Benign, criteria provided, single submittercurationSema4, Sema4May 11, 2021- -
Benign, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthNov 19, 2014- -
Benign, criteria provided, single submitterclinical testingAmbry GeneticsJun 17, 2014This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
not provided Benign:1
Benign, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenApr 01, 2024BARD1: BP4, BS1, BS2 -
Malignant tumor of breast Benign:1
Benign, no assertion criteria providedclinical testingDepartment of Pathology and Laboratory Medicine, Sinai Health System-BARD1, EXON11, c.2212A>G, p.Ile738Val, Heterozygous, Benign The BARD1 p.Ile738Val variant was identified in 5 of 1030 proband chromosomes (frequency: 0.005) from Polish, Australian and Belgian individuals or families with high risk BRCA1/2 negative breast and/or ovarian cancer and was identified in 5 of 1096 control chromosomes (frequency:0.005) from healthy individuals (Ratajska 2012, Gorringe 2008, De Brakeleer 2010). The variant was identified in a breast tumour, and assessed to be a neutral variant based on a transient apoptosis assay that showed no loss of function (Sauer 2005). In addition, the variant is located with the BRCT functional domain(s) increasing the liklihood that it may have clinical significance; however, protein modelling showed no effect on protein structure or stability (De Brakeleer 2010). The variant was also identified in dbSBP (ID: rs61754118) “With Likely benign allele”, ClinVar (classified benign by GeneDx, Ambry Genetics, Invitae, Vantari Genetics, Color Genomics, and Counsyl; and likely benign by Illumina), Clinivitae (4X) and the Zhejiang Colon Cancer Database (5x), but was not identified in Cosmic and MutDB databases. The variant was identified in control databases in 2066 (21 homozygous) of 277076 chromosomes at a frequency of 0.007 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Consortium Feb 27, 2017); being identified in the following populations at a frequency greater than 1%: Ashkenazi Jewish* in 285 of 10150 chromosomes (freq: 0.028), Other in 119 of 6464 chromosomes (freq: 0.018), and Latino in 389 of 34408 chromosomes (freq: 0.011). The p.Ile738Val residue is not conserved in mammals and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information this variant meets our laboratory's criteria to be classified as benign. -
Hereditary breast ovarian cancer syndrome Benign:1
Benign, criteria provided, single submitterclinical testingNational Health Laboratory Service, Universitas Academic Hospital and University of the Free StateApr 19, 2022- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.12
BayesDel_addAF
Benign
-0.60
T
BayesDel_noAF
Benign
-0.63
Cadd
Benign
18
Dann
Benign
0.94
DEOGEN2
Benign
0.10
T;.;.;.;T;.
Eigen
Benign
-0.31
Eigen_PC
Benign
-0.10
FATHMM_MKL
Uncertain
0.91
D
LIST_S2
Benign
0.81
T;T;T;T;T;.
MetaRNN
Benign
0.0065
T;T;T;T;T;T
MetaSVM
Benign
-1.1
T
MutationAssessor
Benign
1.3
L;.;.;.;.;.
MutationTaster
Benign
0.63
D;D;D
PrimateAI
Benign
0.37
T
PROVEAN
Benign
-0.43
N;.;.;.;.;.
REVEL
Benign
0.011
Sift
Benign
0.40
T;.;.;.;.;.
Sift4G
Benign
0.53
T;T;T;T;T;T
Polyphen
0.027
B;.;.;.;.;.
Vest4
0.081
MVP
0.66
MPC
0.074
ClinPred
0.0056
T
GERP RS
4.5
Varity_R
0.036
gMVP
0.51

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs61754118; hg19: chr2-215593522; COSMIC: COSV99638516; COSMIC: COSV99638516; API